KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
- Written by PR Newswire
 |
- Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion
- Research and development expenses was approximately RMB611.5 million
- Loss for the period was RMB145.2 million; adjusted loss for the period[1] was RMB69.4 million
- Cash and cash equivalents[2] amounted to...
